Howells LM, et al. - Researchers compared folinic acid/5-fluorouracil/oxaliplatin chemotherapy (FOLFOX) vs FOLFOX + 2 g oral curcumin/d (CUFOX), for safety, effectiveness, quality of life, neurotoxicity, curcuminoids, and C-X-C-motif chemokine ligand 1 (CXCL1) in patients (n=28, aged >18 years) with a histological diagnosis of metastatic colorectal cancer enrolled in this phase 2a open-labelled randomized controlled trial. Both treatment arms demonstrated similar adverse event profiles. The estimated HR for progression-free survival and for overall survival were 0.57 and 0.34, respectively, in the intention-to-treat population. Neither quality of life nor neurotoxicity significantly differed between arms. CXCL1 was not significantly altered over time by curcumin. Overall, findings established the safety and tolerability of curcumin as an adjunct to FOLFOX chemotherapy in patients with metastatic colorectal cancer.